Description:
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an
antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative
Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB),
which CDX-011 binds to. The study will also further characterize the safety of CDX-011
treatment in this patient population.
Title
- Brief Title: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
- Official Title: A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Clinical Trial IDs
- ORG STUDY ID:
CDX011-04
- NCT ID:
NCT01997333
Conditions
- Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions
Drug | Synonyms | Arms |
---|
CDX-011 | | Drug: CDX-011 |
Capecitabine | | Capecitabine |
Purpose
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an
antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative
Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB),
which CDX-011 binds to. The study will also further characterize the safety of CDX-011
treatment in this patient population.
Detailed Description
CDX-011 consists of an antibody attached to a drug, monomethyl auristatin E (MMAE), that can
kill cancer cells. The antibody delivers the drug to cancer cells by attaching to a protein
called glycoprotein NMB (gpNMB) that is expressed on the cancer cell. The MMAE is then
released inside of the cell, where it interferes with cell growth and may lead to cell death.
This study will examine the efficacy and safety of CDX-011 in patients with advanced TNBC
that makes the gpNMB protein. The effect of CDX-011 will be compared to treatment with
capecitabine.
Eligible patients who enroll in the study will be randomly assigned (by chance) to receive
treatment with CDX-011 or with capecitabine. For every three patients enrolled, two will
receive CDX-011 and one will receive treatment with capecitabine. All patients enrolled in
the study will be closely monitored to determine if their cancer is responding to treatment
and for any side effects that may occur.
Trial Arms
Name | Type | Description | Interventions |
---|
Capecitabine | Active Comparator | Capecitabine will be administered on Days 1 through 14 of each 21 day cycle. | |
Drug: CDX-011 | Experimental | CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle. | |
Eligibility Criteria
Inclusion Criteria:
Among other criteria, patients must meet all of the following conditions to be eligible for
the study:
1. Diagnosed with metastatic (i.e., cancer that has spread) TNBC
- minimal or no expression of estrogen and progesterone receptors (ER/PR) <10% of
cells positive by immunohistochemistry
- HER 2 staining 0 or 1+ by IHC or copy number <4.0 signals/cell
2. Documented progression of disease based on radiographic, clinical or pathologic
assessment during or subsequent to the last anticancer regimen received.
3. Breast cancer tumor confirmed to express gpNMB. This will be determined by submitting
a tissue sample from the advanced (locally advanced/recurrent or metastatic) disease
setting to a central laboratory for analysis.
4. Received no more than two prior chemotherapy treatments for advanced (locally
advanced/recurrent or metastatic) breast cancer.
5. Prior chemotherapy treatment must have contained an anthracycline (e.g. doxorubicin or
Doxil) if clinically indicated and a taxane (eg: Taxol).
6. ECOG performance status of 0 - 1.
7. Adequate bone marrow, liver and renal function.
Exclusion:
Among other criteria, patients who meet any of the following conditions are NOT eligible
for the study:
1. Progression/recurrence of breast cancer during or within 3 months of completion of
neoadjuvant or adjuvant chemotherapy.
2. Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are
moderate (Grade 2) or worse in severity.
3. Known brain metastases, unless previously treated and asymptomatic for 2 months and
not progressive in size or number for 2 months.
4. Significant cardiovascular disease.
5. Previously received capecitabine and discontinued due to progression or intolerance;
previously received CDX-011 or other MMAE containing agents.
6. Active systemic infection requiring treatment. Infection controlled by oral therapy
will not be exclusionary.
7. Chronic use of systemic corticosteroids.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Progression Free Survival (PFS) |
Time Frame: | Evaluated every 6 - 9 weeks following treatment initiation |
Safety Issue: | |
Description: | PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or progression in a non-target lesion, or the appearance of new lesions. The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee, blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria. |
Secondary Outcome Measures
Measure: | Objective Response Rate (ORR) |
Time Frame: | Evaluated every 6 - 9 weeks following treatment initiation |
Safety Issue: | |
Description: | ORR is defined as the percentage of patients who achieve best overall response of complete or partial response. The analysis of ORR was based on ORR events determined retrospectively by the central independent review committee, blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), Complete Response (CR) = Disappearance of all target lesions and non-target lesions, Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions with no progression in non-target lesions and no new lesions. |
Measure: | Duration of Response |
Time Frame: | Evaluated every 6 - 9 weeks following treatment initiation |
Safety Issue: | |
Description: | Duration of response (DOR) is the number of months from the time criteria are first met for either CR or PR, until the first date that PD is objectively documented. The analysis of DOR was determined retrospectively by the central independent review committee,blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), Complete Response (CR) = Disappearance of all target lesions and non-target lesions, Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions with no progression in non-target lesions and no new lesions. |
Measure: | Overall Survival |
Time Frame: | During treatment and 3 months from end of treatment through end of study or approximately up to 5 years. |
Safety Issue: | |
Description: | Overall Survival (OS) is defined as the number of months from randomization to the date of death due to any cause. |
Measure: | Adverse Events (AE) |
Time Frame: | Usually following at least 1 cycle of study treatment (1 dose of CDX-011 or capecitabine and until discontinuation of follow-up) |
Safety Issue: | |
Description: | The percentage of patients experiencing one or more adverse events will be summarized by treatment arm, relationship to study drug, and severity. |
Measure: | Pharmacokinetics (PK) |
Time Frame: | Following 1 dose of CDX-011. |
Safety Issue: | |
Description: | Concentration of the antibody drug conjugate (ADC), total antibody (TA) and free MMAE will be determined. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Celldex Therapeutics |
Trial Keywords
- Metastatic Breast Cancer
- Locally advanced breast cancer
- Breast cancer
- Triple negative
- Estrogen
- Progesterone
- HER2 receptors
- Targeted treatment for breast cancer
- Antibody-drug-conjugate
- Breast Neoplasms
- CDX-011
- gpNMB
- METRIC
- Glembatumumab vedotin
- Triple Negative Breast Cancer
- TNBC
Last Updated
March 8, 2019